Press/Media
- 1 - 25 out of 224 results
Search results
-
Diabetes drug fights stroke: Researchers say Sotagliflozin can reduce heart attacks too
15/02/25
1 item of Media coverage
Press/Media
-
US FDA-approved diabetes drug shows promise against heart attacks, strokes: Study
15/02/25
1 item of Media coverage
Press/Media
-
Weekly: Tourmaline Bio (TRML: $13.83) falls for a sixth consecutive week, a six-week fall of 35%; -45c [3.2%]
15/02/25
1 item of Media coverage
Press/Media
-
US FDA-Approved Diabetes Drug Shows Promise Against Heart Attacks, Strokes: Study
15/02/25
13 items of Media coverage
Press/Media
-
‘First of its kind’ medication can significantly reduce heart attacks and strokes
15/02/25
2 items of Media coverage
Press/Media
-
SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney Disease
14/02/25
1 item of Media coverage
Press/Media
-
-
A diabetes, heart failure, and kidney disease medication is the first of its kind to significantly reduce both heart attacks and strokes
14/02/25
2 items of Media coverage
Press/Media
-
Weekly: Tourmaline Bio (TRML: $14.28) accelerates decline: down 19% in 2 weeks; -$1.78 [11.1%] Vol Index 1.5 [1 is avg]
8/02/25
1 item of Media coverage
Press/Media
-
Tourmaline Bio plummets 52% in past year, underperforming 81% of the market
4/02/25
1 item of Media coverage
Press/Media
-
Monthly: Tourmaline Bio (TRML: $16.06) falls for a third consecutive month, a three-month fall of 37%
3/02/25
1 item of Media coverage
Press/Media
-
Weekly: Tourmaline Bio (TRML: $17.54) falls for a third consecutive week, a three-week fall of 18%; -46c [2.6%]
25/01/25
1 item of Media coverage
Press/Media
-
The year in thrombosis, CAD: New PCI populations and DAPT strategies
24/01/25
1 item of Media coverage
Press/Media
-
Weekly: Tourmaline Bio (TRML: $18.0) sinks 9% on average volume; -$1.70 [8.6%]
18/01/25
1 item of Media coverage
Press/Media
-
Weekly: Tourmaline Bio (TRML: $19.70) shares post worst week in three weeks; -94c [4.6%]
11/01/25
1 item of Media coverage
Press/Media
-
-
-
Weekly: Tourmaline Bio (TRML: $21.43) rises for a second consecutive week, a two-week rise of 3.8%; +75c [3.6%]
4/01/25
1 item of Media coverage
Press/Media
-
Monthly: Tourmaline Bio (TRML: $20.28) drops 22% on high volatility in December 2024
2/01/25
1 item of Media coverage
Press/Media
-
Top cardiology video interviews in 2024
Reddy, V. Y. & Bhatt, D. L.
2/01/25
1 item of Media coverage
Press/Media
-
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA
2/01/25
1 item of Media coverage
Press/Media
-
End-of-Quarter Synopsis Monthly : Tourmaline Bio (TRML: $20.28) drops 22% on high volatility in December 2024
31/12/24
1 item of Media coverage
Press/Media
-
Weekly: Tourmaline Bio (TRML: $20.68) increases on weak volume; +3c [0.1%]
28/12/24
1 item of Media coverage
Press/Media
-
Weekly: Tourmaline Bio (TRML: $20.65) keeps sliding: down 21% in 3 weeks; -$1.16 [5.3%]
21/12/24
1 item of Media coverage
Press/Media